Lupin Ltd. has signed an in-licensing agreement with ItalFarmaco, a leading Italian pharmaceutical company. As per the agreement, Lupin will exclusively market their cardiovascular critical care product, Enoxaparin Sodium Injection, in pre-filled syringes under the brand name "Lupenox" in the Indian market.
"Lupin has always made quality products affordable to Indian patients. Our tie-up with ItalFarmaco is yet another effort in this direction. In life critical situations, quality is of paramount importance. We believe Lupenox, being a superior quality product sourced from ItalFarmaco's USFDA approved facility, will serve the needs of patients better," said Sakti Chakraborty, President - India Region Formulations, Lupin Ltd.
Diego, General Manager, ItalFarmaco said: "Lupin is the right Marketing partner that ItalFarmaco always wanted to partner with because of its strong marketing presence in the Indian Pharmaceutical market. ItalFarmaco strongly believes that Lupin is fully equipped to market and promote Lupenox to doctors, pharmacists, and help millions of deserving Indian patients use our product and improve their health."